Bausch Health Companies (BHC) 10-Q2024 Q1 Quarterly report

Filed: 2 May 24, 4:57pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abeyance, Ahuja, Alladina, Alpha, Amneal, AP, appellant, Appellate, Aspen, ASU, attractive, awaiting, Bahaa, Bharat, billion, Boeing, Brahman, buying, CABTREO, capped, catastrophic, cease, climate, Colonial, comfort, commodity, Commonwealth, copyright, costly, Council, Crohn, CT, damage, denial, dietary, digitalisation, distributor, DRL, Dynamic, Dynasty, economy, edge, Elidel, EMA, endoscopic, FASB, faster, Foinaven, Fonden, GIC, GMO, GMTA, IlluminationsTM, Incline, intensify, intention, IRA, Kowalyshyn, Lanham, led, Levered, Los, maker, Maverick, Medicare, member, memorandum, MNE, MSD, multinational, narrow, Neutral, noncompliance, Northwestern, nuisance, OECD, Okeley, OPG, Opportunistic, outperformance, payout, pillar, pledged, political, preferred, prohibited, Prudential, recessionary, reconsider, redesigning, redirecting, Relistor, reopened, residual, respond, restitution, reward, rotation, Sandoz, stable, stoppage, Sukenaga, Suspension, Templeton, timetable, topline, Torchlight, traditional, Treasurer, Trust, Trustee, undertaxed, Union, University, USAA, VALIC, vii, viii, Wellbutrin

Removed: abroad, adapalene, anniversary, appointment, assigned, Auro, Aurobindo, begun, benzoyl, BLCO, bond, bps, breadth, Brent, budesonide, budget, build, Carolyn, cell, chargeback, clindamycin, comment, concluding, constituted, contemplated, contracting, creating, Cuprimine, dealing, dealt, declaration, declared, decreased, deductibility, deducting, degeneration, deposited, directing, director, dosage, ease, enforced, enrolling, entrant, establishing, exchanging, expire, finalization, fit, GmbH, harm, high, impaired, Inactive, incentivize, inflationary, intentionally, intestinal, irrevocably, issuer, likelihood, linked, Logan, logistic, main, medicine, Mellon, Microsphere, minimal, Missouri, netted, Nifediac, Noritate, noting, Novaliq, Nuvessa, Ocuvite, omicron, orphan, Ortho, outbreak, overgrowth, pandemic, pension, peroxide, pertaining, phosphate, postretirement, predicted, Prolensa, prospectively, publicity, question, recourse, reflecting, registered, registration, reinstitution, relation, reputational, restoration, resurgence, ROTC, RSU, scientific, Shanghai, shelter, SIBO, sickle, sourcing, steroid, suggest, suspend, suspended, tangible, Targretin, ticker, tool, trading, unbranded, underwriting, unlocked, unvested, upcoming, validated, variant, version, vested, Xerese, ZeaVision

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BHC transcripts

BHC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas J. Appio, Chief Executive Officer of Bausch Health Companies Inc. (the “Company”), certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:			May 2, 2024
/s/ THOMAS J. APPIO
Thomas J. Appio
Chief Executive Officer (Principal Executive Officer)

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.